Abstract: The present disclosure provides a pharmaceutical composition for treating Alzheimer's disease and use thereof, the pharmaceutical composition containing, as an active ingredient, stem cells (SC) having high adaptability under hypoxic conditions. Particularly, the present disclosure discloses a pharmaceutical composition for alleviating or treating the symptoms of Alzheimer's disease, the pharmaceutical composition containing, as an active ingredient, mesenchymal stem cells (MSC) which have high adaptability or viability in hypoxic environments and comprise one or more knock-out HIF1AN genes.

Abstract: The present invention relates to a human Lefty A protein variant with improved productivity and stability, a fusion protein comprising the protein variant, and a composition for preventing and/or treating neuromuscular disease comprising the protein variant or the fusion protein. According to the present invention, a human Lefty A protein variant and a fusion protein comprising the variant are constructed, which have better stability than naturally occurring human Lefty A protein, and thus are expressed at high levels and produced in high yield in animal cells. In addition, administration of the constructed human Lefty A protein variant or fusion protein can restore the nerve and motor functions of nerve disease model animals. Accordingly, the use of the human Lefty A protein variant or fusion protein can effectively prevent or treat various nerve diseases and muscle diseases.

Abstract: The present invention relates to a composition for enhancing a survival rate of stem cells, including an immunosuppressant, and to a use thereof. According to the present invention, a survival rate of stem cells can be remarkably enhanced using a composition including an immunosuppressant, and a therapeutic effect of stem cells can be improved on the basis of the enhancement. The composition can overcome an immune response caused by the administration of xenogeneic cells so as to accurately verify the stability and efficacy of cells, and thus will be able to be utilized as a mesenchymal stem cell therapeutic agent that maximizes a therapeutic effect of stem cells.

Abstract: A gate driver includes a plurality of gate stages. Each of the plurality of gate stages includes a carry generating circuit outputting a second carry signal having a phase which is later than a phase of a first carry signal, on the basis of a first clock signal and a second clock signal having different phases and a scan generating circuit outputting a scan signal having a phase which differs from phases of the first and second carry signals, on the basis of the first clock signal, the second clock signal, and the first carry signal. Each of the first clock signal, the second clock signal, the first carry signal, and the second carry signal may be a P-type pulse, and the scan signal may be an N-type pulse.

Abstract: A hybrid air mobility system is capable of flying a long distance through effective operation of an engine and batteries. The hybrid air mobility system includes a fuselage configured to supply power to a propeller and electric equipment, the fuselage being provided with a duct including an inlet and an outlet so as to circulate air to the engine and the electric equipment; a deflector rotatably installed at the outlet of the duct so as to convert a discharge direction of exhaust gas generated by the engine and cooling air after cooling the electric equipment; and a controller configured to determine whether or not the engine is driven and to control a rotated position of the deflector depending on an amount of driving of the engine so as to selectively adjust movement of the exhaust gas and the cooling air towards the propeller.

Abstract: Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.

Abstract: A device comprises memory, a display characterized by a display characteristic, and processors coupled to the memory. The processors execute instructions causing the processors to receive data indicative of the display characteristic, data indicative of ambient lighting, and data indicative of content characteristics for a content item; determine a tone mapping curve for the content item based on the data indicative of content characteristics; determine a first, so-called “anchor” point along the tone mapping curve; modify a first portion of the tone mapping curve below the anchor point based on the data indicative of ambient lighting; modify a second portion of the tone mapping curve above the anchor point based on the data indicative of the display characteristic; perform tone mapping for the content item based on the modified toned mapping curve to obtain a tone mapped content item; and cause the display to display the tone mapped content item.

Abstract: The present application relates to a marker gene for detecting the proliferative ability of stem cells and uses thereof, and provides a marker detection composition for detecting the proliferative ability of stem cells, a kit for detecting the proliferative ability of stem cells, and a composition for improving the proliferative ability of stem cells, etc. According to the composition or method according to an aspect, stem cells having a high proliferative ability may be easily selected, and the proliferative ability of stern cells may be significantly improved.

Abstract: A touch display device for preventing the occurrence of a short circuit between routing lines is disclosed. The touch display device includes a dam forming a boundary with an encapsulation unit covering a light-emitting element, and the dam is formed such that the height thereof in a region that overlaps routing lines, which are connected to touch electrodes disposed on the encapsulation unit, and the height thereof in a region that does not overlap the routing lines are different from each other, thereby preventing the occurrence of a short circuit between the routing lines.

Abstract: Disclosed are a pixel driving circuit and an electroluminescent display device including the same. The pixel driving circuit in each of the pixels includes: a first switching circuit that turned on in response to the (n-2)th scan signal to provide a V1 voltage to a first node, provide a V3 voltage to a third node, and provide a V2 voltage to an anode of the light-emitting element; a second switching circuit turned on in response to the nth scan signal to electrically connect the first node to a second node, provide a V5 voltage to the third node, and provide a data voltage to a fourth node; and an emission control circuit turned on in response to the nth emission signal to electrically connect a second node to the anode and provide a reference voltage to the fourth node.

Abstract: The present invention relates to methods of metabolic engineering bacteria cells to produce bile salt hydrolase to inhibit the germination of C. difficile endospores and colonisation within the human gastrointestinal tract. The bile salt hydrolase is operably linked to a sialic acid-inducible promoter, pNanA, of which pNanA is in turn controlled by the repressor nanR. The recombinant bacteria expressing the bile salt hydrolase can be a probiotic strain to be used for prophylaxis or treatment of C. difficile infection.

Abstract: A touch display device for preventing the occurrence of a short circuit between routing lines is disclosed. The touch display device includes a dam forming a boundary with an encapsulation unit covering a light-emitting element, and the dam is formed such that the height thereof in a region that overlaps routing lines, which are connected to touch electrodes disposed on the encapsulation unit, and the height thereof in a region that does not overlap the routing lines are different from each other, thereby preventing the occurrence of a short circuit between the routing lines.

Abstract: A pixel driving circuit in each of the pixels includes: a first switching circuit that is turned on in response to the (n?2)th scan signal to provide a V1 voltage to a first node, provide a V3 voltage to a third node, and provide a V2 voltage to an anode of the light-emitting element; a second switching circuit turned on in response to the nth scan signal to electrically connect the first node to a second node, provide a V5 voltage to the third node, and provide a data voltage to a fourth node; and an emission control circuit turned on in response to the nth emission signal to electrically connect a second node to the anode and provide a reference voltage to the fourth node.

Abstract: A display device includes a base, a light emitting element disposed on the base, a capping layer disposed on the light emitting element, a thin-film encapsulation layer which is disposed on the capping layer and includes an inorganic layer at the bottom, and a wavelength conversion pattern which is disposed on the thin-film encapsulation layer and overlaps the light emitting element. The capping layer includes a first sub-capping layer disposed on the light emitting element and a second sub-capping layer disposed between the first sub-capping layer and the inorganic layer, and a refractive index of the second sub-capping layer is greater than a refractive index of the inorganic layer and smaller than a refractive index of the first sub-capping layer.

Abstract: The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

Abstract: The present disclosure provides a display device having a touch sensor for reducing the size of a bezel area. The display device having a touch sensor is configured such that touch electrodes and touch lines are disposed in a mesh shape on an encapsulation layer encapsulating light-emitting elements and such that some of the touch lines are connected to a touch-driving circuit via an upper bezel area, thereby reducing the size of left and right bezel areas.

Abstract: The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.

Abstract: The present disclosure provides a display device having a touch sensor for reducing the size of a bezel area. The display device having a touch sensor is configured such that touch electrodes and touch lines are disposed in a mesh shape on an encapsulation layer encapsulating light-emitting elements and such that some of the touch lines are connected to a touch-driving circuit via an upper bezel area, thereby reducing the size of left and right bezel areas.

Abstract: The present disclosure provides a touch display device for minimizing viewing-angle-dependent variation in color coordinates. The touch display device includes a light-emitting element disposed in each of a plurality of subpixels including emission areas having different sizes, a plurality of touch electrodes disposed on the light-emitting element, and at least one opening formed in each of the plurality of touch electrodes. The width of the opening is formed differently in each of the plurality of subpixels including the emission areas having different sizes, thereby minimizing viewing-angle-dependent variation in color coordinates.